Skip to main content
SpringerLink
Log in

ANDROLOGY

Testosterone therapy and medical hysteria

  • News & Views
  • Published:

From Nature Reviews Urology

View current issue Sign up to alerts

A recent study has shown a decline in testosterone prescriptions since media reports of potential increased cardiovascular risk in 2014. The phenomenon of medical hysteria accounts for this reduced prescribing, as numerous subsequent studies provide substantial evidence of reduced cardiovascular risk and other important benefits with testosterone therapy for men with testosterone deficiency.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1: The number of studies since 2015 reporting increased, decreased, or no difference (neutral) in MACE with testosterone therapy.

References

  1. Traish, A. M., Vance, J. C. & Morgentaler, A. Overselling hysteria: the role of the media and medical journals in promoting questionable risks-a case study of the testosterone controversy. EMBO Rep. 18, 11–17 (2017).

    Article  CAS  Google Scholar 

  2. Vigen, R. et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA 310, 1829–1836 (2013); erratum 311, 967 (2014).

    Article  CAS  Google Scholar 

  3. Baillargeon, J. et al. Testosterone prescribing in the United States, 2002-2016. JAMA. 320, 200–202 (2018).

    Article  Google Scholar 

  4. Morgentaler, A. et al. Testosterone therapy and cardiovascular risk: advances and controversies. Mayo Clin. Proc. 90, 224–251 (2015).

    Article  CAS  Google Scholar 

  5. Traish, A. M., Guay, A. T. & Morgentaler, A. Death by testosterone? We think not! J. Sex. Med. 11, 624–629 (2014).

    Article  Google Scholar 

  6. Morgentaler, A. & Lunenfeld, B. Testosterone and cardiovascular risk: world’s experts take unprecedented action to correct misinformation. Aging Male 17, 63–65 (2014).

    Article  Google Scholar 

  7. Miner, M. et al. The state of testosterone therapy since the FDA’s 2015 labelling changes: indications and cardiovascular risk. Clin. Endocrinol. (Oxf.). 89, 3–10 (2018).

    Article  Google Scholar 

  8. US Food and Drug Administration. http://www.fda.gov/fdac/departs/196_upd.html (Accessed 6 March 2007).

  9. Baillargeon, J. et al. Screening and monitoring in men prescribed testosterone therapy in the U. S., 2001–2010. Publ. Health Rep. 130, 143–152 (2015).

    Article  Google Scholar 

  10. Morgentaler, A. et al. Fundamental concepts regarding testosterone deficiency and treatment: international expert consensus resolutions. Mayo Clin. Proc. 9, 881–896 (2016).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Harvard Medical School, Boston, MA, USA

    Abraham Morgentaler

Authors
  1. Abraham Morgentaler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Abraham Morgentaler.

Ethics declarations

Competing interests

A.M. has received payments from Acerus for lecture honoraria, Aytu for consulting, and Endo for research grants.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Morgentaler, A. Testosterone therapy and medical hysteria. Nat Rev Urol 15, 659–660 (2018). https://doi.org/10.1038/s41585-018-0081-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41585-018-0081-2

  • Springer Nature Limited

Search

Navigation